Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Preferred Stock Liabilities (2017 - 2018)

Crinetics Pharmaceuticals has reported Preferred Stock Liabilities over the past 2 years, most recently at $93.0 million for Q2 2018.

  • For Q2 2018, Preferred Stock Liabilities changed N/A year-over-year to $93.0 million; the TTM value through Jun 2018 reached $93.0 million, changed N/A, while the annual FY2017 figure was $29.7 million, 67.42% up from the prior year.
  • Preferred Stock Liabilities for Q2 2018 was $93.0 million at Crinetics Pharmaceuticals, up from $29.7 million in the prior quarter.
  • Over five years, Preferred Stock Liabilities peaked at $93.0 million in Q2 2018 and troughed at $29.7 million in Q4 2017.